Full-Time

Senior Director

Finance and Operations

Updated on 8/19/2026

Revolution Medicines

Revolution Medicines

1,001-5,000 employees

Clinical-stage oncology company developing RAS inhibitors

Compensation Overview

CA$196k - CA$245k/yr

+ Equity awards + Cash compensation

Remote in Canada

Remote

Bachelor's, MBA

Category
Accounting (2)
,
Required Skills
Supply Chain Management
Financial analysis

Get referred to Revolution Medicines

See people who can refer or advise you

Requirements
  • Financial education is required.
  • At least 10 years of finance experience in a public global biopharmaceutical company is required.
  • Experience as the head of finance for a Canadian affiliate is required.
  • The candidate must be able to think strategically across different functional areas and evaluate multiple perspectives, variables, options, and recommendations.
  • The candidate must possess financial analytical, problem-solving, and business judgment skills, with the ability to transition from strategic thinking to tactical execution.
  • The candidate must be able to manage projects involving multiple cross-functional stakeholders, including project scope, timelines, team integration, and deliverable quality and timeliness.
  • The candidate must demonstrate the ability to align and motivate a team to achieve financial results, timely and accurate reporting, transparency, and controls.
  • Experience with supply chain management and logistics in both local and global contexts is required.
  • The candidate must be able to build and nurture a culture of collaboration and authenticity.
  • The candidate must possess strong organization, motivation, communication, presentation, and interpersonal skills.
Responsibilities
  • Serve as the head of Finance and Operations in Canada and Country Chief Financial Officer.
  • Develop and manage all financial and key operational functions for the Canadian affiliate.
  • Support development and execution of the strategy to build the Canadian team and launch the company and portfolio in Canada.
  • Contribute to pre-launch and launch strategic and operational plans.
  • Establish Canadian processes and policies.
  • Work with stakeholders on Canadian supply chain and distribution plans.
  • Lead and coordinate Canada finance and supply chain functions to support product launches.
  • Oversee Canadian accounting, financial planning and analysis, treasury, tax, payroll, procurement, and internal controls.
  • Collaborate with global accounting and tax teams to ensure financial reporting and compliance for Canadian and, where needed, JPAC legal entities.
  • Ensure appropriate accounting treatment for Canadian contracts and agreements, including revenue recognition.
  • Develop and manage Canadian financial strategies to support business growth and financial health.
  • Implement and drive process improvements in systems and processes with corporate Accounting, Financial Planning and Analysis, Human Resources, Legal, and Information Technology functions.
  • Partner with Corporate Tax on transfer pricing, intercompany agreements, value-added tax, and tax filings.
  • Lead budgeting and financial planning activities, including the Long Range Plan, across the Canadian market.
  • Develop and manage Canadian profit-and-loss statements and support potential JPAC expansion.
  • Oversee analysis of financial and operational results against plan and investigate significant profit-and-loss variances.
  • Support commercial teams with financial business planning, market access strategies, and pricing plans for Canadian markets.
  • Align business objectives with financial and operational goals across cross-functional teams.
  • Lead Canadian financial audits.
  • Establish and lead the internal control framework with Corporate Accounting.
  • Set up the Canadian commercial distribution channel and order-to-cash activities with key stakeholders and third-party logistics providers.
  • Provide local operational support for international distribution and trade, including supply chain management, logistics, and inventory control.
  • Support compliance with international trade regulations, import/export laws, tariffs, customs requirements, and other regulatory requirements for international operations.
  • Manage relationships with international and Canadian suppliers, distributors, and logistics providers.
  • Collaborate with manufacturing teams to support supply chain activities until a dedicated supply chain function is established.
  • Lead and coordinate Canada finance-related staff functions during the initial phase of Canadian operations expansion.
  • Serve as the Finance point person for Canadian functions, including payroll.
  • Manage local procurement and vendor management activities.
  • Collaborate with Corporate Accounting and Financial Planning and Analysis to align the global finance organization.
  • Develop and implement strategic initiatives supporting Canadian growth objectives.
Desired Qualifications
  • MBA, Certified Public Accountant, Chartered Accountant, or Chartered Financial Analyst qualification is preferred.
  • Prior experience working with a third-party logistics provider and building, selecting, or negotiating an appropriate logistics model is preferred.

Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Revolution Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted daraxonrasib NDA on July 22, 2026 for previously treated metastatic pancreatic cancer.
  • BeOne will fund a global Phase 3 study and pay milestones plus Asian royalties.
  • Cash and marketable securities reached $3.9 billion on June 30, 2026, extending runway.

What critics are saying

  • FDA acceptance on July 22, 2026 starts review; rejection kills the lead thesis.
  • Commercial launch needs payer adoption against cheap chemotherapy and entrenched oncology incumbents by 2027.
  • A failed RASolve 301 readout or safety signal would crater the entire RAS(ON) platform.

What makes Revolution Medicines unique

  • Daraxonrasib posted 13.2-month median OS in RASolute 302 on April 13, 2026.
  • Revolution Medicines targets active RAS(ON), spanning KRAS G12X, G12D, and G12V biology.
  • August 10, 2026 BeOne deal validates a portfolio, not just one pancreatic asset.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-4%

2 year growth

-4%
Ticker Report
Aug 16th, 2026
Centric Wealth Management Makes New $505,000 Investment in Revolution Medicines, Inc. $RVMD

Centric Wealth Management purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) during the second quarter, HoldingsChannel.com reports. The fund purchased 3,416 shares of the company’s stock, valued at approximately $505,000. Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. […]

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

nuaxia
Aug 12th, 2026
BeOne and Revolution Medicines partner on RAS-targeted oncology combinations and Asian licensing deal.

BeOne and Revolution Medicines partner on RAS-targeted oncology combinations and Asian licensing deal. The collaboration pairs BeOne's oncology pipeline with four clinical-stage RAS(ON) inhibitors while giving BeOne regional rights to the Revolution Medicines assets across selected Asian markets. BeOne Medicines and Revolution Medicines have entered a multi-part oncology collaboration covering combination studies involving BeOne pipeline assets and four clinical-stage RAS(ON) inhibitors - daraxonrasib, zoldonrasib, elironrasib and RMC-5127 - alongside exclusive regional development and commercialisation rights in selected Asian markets. The agreement combines BeOne's development and regional commercial infrastructure with Revolution Medicines' RAS-targeted portfolio and creates opportunities to evaluate new combination approaches for patients with RAS-addicted cancers. | Field | Content | | Alert Type | Deal | | Companies | BeOne Medicines; Revolution Medicines | | Deal Type | Clinical development collaboration and regional licensing agreement | | Asset or Company | Revolution Medicines' daraxonrasib, zoldonrasib, elironrasib and RMC-5127; BeOne's BGB-58067 and BG-T187 among the planned combination assets | | Therapy Area(s) | Oncology; RAS-addicted cancers | | Technology or Modality | RAS(ON) inhibitors; PRMT5 inhibitor; trispecific EGFR x MET x MET antibody | | Deal Value | Financial terms were not fully disclosed. Revolution Medicines is eligible to receive development and sales milestone payments plus tiered royalties on net sales from the licensed Asian territories. | | Development Stage | Clinical stage; the four Revolution Medicines RAS(ON) inhibitors are in clinical development, with BeOne also responsible for funding and conducting a global registrational Phase III trial for one of the assets. | | Geography | Global clinical collaboration plus selected Asian markets for licensed rights. Revolution Medicines retains rights outside the licensed territories, including Japan and South Korea. | | What Happened | On 11 August 2026, BeOne Medicines and Revolution Medicines announced a multi-part collaboration focused on RAS-addicted cancers. The companies plan to evaluate combinations of BeOne pipeline assets, including the MTA-cooperative PRMT5 inhibitor BGB-58067 and trispecific EGFR x MET x MET antibody BG-T187, with Revolution Medicines' four clinical-stage RAS(ON) inhibitors: daraxonrasib, zoldonrasib, elironrasib and RMC-5127. Separately, Revolution Medicines granted BeOne exclusive development and commercialisation, or commercialisation-only rights depending on the territory, for the four RAS(ON) inhibitors in selected Asian markets. BeOne will also fund and conduct a global registrational Phase III trial for one of the Revolution Medicines assets. | | Why It Matters | The agreement extends the development opportunities for Revolution Medicines' RAS(ON) portfolio beyond monotherapy by testing combinations with mechanistically different oncology assets from BeOne. It also gives BeOne access to four clinical-stage RAS-targeted programmes across selected Asian markets, allowing the company to use its development and commercial infrastructure to support their regional development and potential launches. | | Supporting Context | RAS alterations are important oncogenic drivers across multiple tumour types and have historically been difficult to target therapeutically. Revolution Medicines is developing RAS(ON) inhibitors designed to target active RAS proteins, while BeOne has a broader oncology pipeline containing potential combination partners with different mechanisms of action. | | Strategic Rationale | Revolution Medicines gains access to BeOne's oncology assets for combination studies while retaining development and commercial rights to its RAS(ON) programmes outside the licensed Asian territories. BeOne gains regional rights to four clinical-stage RAS inhibitors and the opportunity to evaluate its existing oncology pipeline in combinations that could potentially broaden the therapeutic application of both companies' programmes. | | Potential Impact | Successful studies could establish additional combination strategies for RAS-addicted cancers and broaden the development opportunities for both companies' oncology pipelines. Any clinical or commercial impact will depend on trial results and subsequent regulatory approvals. | | Key Takeaway | The collaboration combines BeOne's oncology pipeline and Asian development infrastructure with four Revolution Medicines RAS(ON) inhibitors, creating both new combination programmes and a regional commercial partnership. | | What to Watch | Initiation and results of the planned combination studies, identification of the RAS(ON) inhibitor selected for BeOne's global registrational Phase III trial and subsequent development and regulatory progress across the licensed Asian territories. | | Primary Source | BeOne Medicines / Revolution Medicines collaboration announcement | | Relevant Date | 11 August 2026 | Discover how nuaxia can support your next medical education initiative:

The Montreal Gazette
Aug 10th, 2026
BeOne Medicines and Revolution Medicines announce clinical development and Regional commercialization collaboration.

BeOne Medicines and Revolution Medicines announce clinical development and Regional commercialization collaboration. Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets SAN CARLOS, Calif. & REDWOOD CITY, Calif. - BeOne Medicines Ltd. (Nasdaq: ONC; HKEX:...

Associated Press
Aug 5th, 2026
Revolution Medicines files daraxonrasib NDA for pancreatic cancer, raises $2.2B

Revolution Medicines announced second quarter 2026 financial results, reporting cash and marketable securities of $3.9 billion as of 30 June. The company completed concurrent public offerings totalling $2.2 billion in gross proceeds and received $250 million from Royalty Pharma. The FDA accepted the company's new drug application for daraxonrasib to treat previously treated metastatic pancreatic cancer. Over 2,000 patients have received the drug through an expanded access programme since May. The FDA also granted breakthrough therapy designation for daraxonrasib in certain non-small cell lung cancer patients. Research and development expenses rose to $394.9 million from $224.1 million year-over-year, whilst general and administrative expenses increased to $110.2 million from $40.6 million. Net loss totalled $644.4 million, compared to $247.8 million in the prior year quarter.